There is no FDA-approved or standard definition of a tirzepatide “microdose.” Zepbound’s lowest approved starting dose is 2.5 mg once weekly, so doses below 2.5 mg are often called microdoses, but that is not an official dosing category 1. Cost varies by source; at Chia, tirzepatide starts at $249/month for tablets and $299/month for injections, with microdosing plans available when clinically appropriate.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →How much is a microdose of tirzepatide?
A tirzepatide microdose usually means a dose below the FDA-approved 2.5 mg once-weekly starting dose, but there is no official standard for that word. The term is mostly used in patient searches, news coverage, and some clinical programs, not in FDA labeling or major tirzepatide trials 1, 2.
Tirzepatide is the active ingredient in Zepbound, approved for chronic weight management, and Mounjaro, approved for type 2 diabetes. It is a dual GLP-1/GIP receptor agonist, meaning it works on two hormone pathways involved in appetite regulation, satiety, delayed gastric emptying, and insulin secretion 1, 2.
Quick facts: tirzepatide microdose amounts, cost, and evidence
- FDA labels for Zepbound and Mounjaro start at 2.5 mg once weekly, then increase based on the product label and clinical judgment 1, 2.
- The Zepbound label states that 2.5 mg is for treatment initiation and is not an approved maintenance dose 1.
- Doses below 2.5 mg weekly are often discussed as “microdoses,” but they were not the main doses tested in large tirzepatide weight-loss trials 3.
- At Chia, tirzepatide tablets and injections are available after licensed-provider review, with plans currently starting at $249/month for tablets and $299/month for injections.
Why “microdose” does not have one official medical definition
In FDA labeling, tirzepatide doses are listed as starting, escalation, and maintenance doses. “Microdose” does not appear as a defined tirzepatide dose category in the Zepbound or Mounjaro labels 1, 2.
That matters because a label dose has been reviewed for a specific use, route, and schedule. A microdose is more of a clinical approach or patient-facing term. It may be considered by some clinicians for tolerability or gradual dose adjustment, but the evidence base is limited.
How microdosing differs from staying on the lowest approved starting dose
Staying at 2.5 mg is not the same thing as using a dose below 2.5 mg. The first is a labeled starting amount; the second is outside the FDA-approved dose range for brand-name tirzepatide products 1, 2.
The safety questions are also different. At 2.5 mg, clinicians can refer to FDA labeling and trial experience. Below 2.5 mg, there is less direct evidence on weight, side effects, missed response, and long-term outcomes.
What are the FDA-approved tirzepatide doses?
The FDA-approved tirzepatide dose range for both Zepbound and Mounjaro starts at 2.5 mg once weekly and can increase in steps to 15 mg once weekly. The reason for use, medical history, side effects, and response guide how a clinician manages titration 1, 2.
Zepbound dosing for weight management: 2.5 mg to 15 mg once weekly
Zepbound is FDA-approved for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related condition, and for certain adults with obstructive sleep apnea and obesity. Its labeled starting dose is 2.5 mg once weekly for 4 weeks, followed by escalation to 5 mg once weekly; maintenance doses are 5 mg, 10 mg, or 15 mg once weekly 1.
Common side effects in tirzepatide trials and labeling include nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. Warnings include pancreatitis risk, gallbladder disease, kidney injury from dehydration, and hypoglycemia risk when combined with insulin or sulfonylureas 1.
Mounjaro dosing for type 2 diabetes: 2.5 mg to 15 mg once weekly
Mounjaro is FDA-approved to improve blood sugar control in adults with type 2 diabetes, along with diet and exercise. Its labeled starting dose is also 2.5 mg once weekly for 4 weeks, with dose increases in 2.5 mg steps as described in the label 2.
For type 2 diabetes, clinicians pay close attention to glucose trends and other diabetes medications. The Mounjaro label warns that hypoglycemia risk can rise when tirzepatide is used with insulin or sulfonylureas 2.
Why 2.5 mg is a starting dose, not usually considered a microdose
The Zepbound label states that 2.5 mg is used to start treatment and is not approved as a maintenance dosage 1. That does not mean every patient must move up on the same timeline, but it does mean 2.5 mg is best understood as the labeled entry dose, not an official microdose.
What dose amounts are people calling tirzepatide microdoses?
In common use, tirzepatide microdosing usually refers to amounts below 2.5 mg weekly. These amounts are discussed online and in some clinical settings, but they are not FDA-approved labeled doses and have not been tested like the main doses used in large trials.
Commonly discussed ranges below 2.5 mg weekly
Some programs describe fractional doses below the usual starting dose, but there is no single validated tirzepatide microdose range. Because definitions vary, the safer way to think about “microdose” is not as a number to copy, but as a clinician-guided low-dose strategy with limited evidence below labeled ranges 1, 3.
Why online dose examples should not be copied
Online dose examples can be risky because they do not account for BMI, metabolic health, medications, side effects, gallbladder history, pancreatitis history, kidney function, diabetes status, pregnancy plans, or contraindications. Tirzepatide labels warn against use in people with a personal or family history of medullary thyroid carcinoma or in people with MEN2 1, 2.
Changing a prescribed dose or spacing injections differently can also make effects harder to predict. Because tirzepatide slows gastric emptying and affects glucose regulation, dose changes should be reviewed by a clinician 1, 2.
Dosing chart: approved doses vs commonly discussed microdose ranges vs evidence status
| Dose category | Example amount | Evidence status | What it means for patients |
|---|---|---|---|
| FDA-approved starting dose | 2.5 mg once weekly | Listed in Zepbound and Mounjaro FDA labels | Used to start therapy; Zepbound label says it is not an approved maintenance dose 1, 2 |
| FDA-approved maintenance doses | 5 mg, 10 mg, or 15 mg once weekly for Zepbound | Studied in large weight-management trials and included in FDA labeling | Used when clinically appropriate after titration and follow-up 1, 3 |
| Commonly discussed microdose | Below 2.5 mg weekly | No FDA-approved definition; limited direct clinical trial evidence | Should only be considered with clinician oversight, if used at all |
| Self-adjusted dose splitting or stretching | Varies | Not a validated dosing plan | Can create safety and consistency problems; do not do this without clinician guidance |
Can you lose weight on 2.5 mg of tirzepatide?
Some people may notice appetite changes on 2.5 mg tirzepatide, but large weight-loss trials mainly evaluated higher maintenance doses. The honest answer is that 2.5 mg is a labeled starting dose, not the main dose used to prove long-term weight outcomes 1, 3.
What clinical trials studied and what they did not prove
In SURMOUNT-1, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly, or placebo, for 72 weeks. Mean weight change was -15.0%, -19.5%, and -20.9% with the 5 mg, 10 mg, and 15 mg doses, compared with -3.1% with placebo; individual results vary 3.
Those results support the active ingredient as studied at trial doses. They do not prove the same outcomes for compounded formulations, and compounded drugs are not FDA-approved or evaluated by FDA for safety, effectiveness, or quality before marketing 8.
The same trials also showed gastrointestinal side effects, most often nausea, diarrhea, and constipation, especially during dose escalation 3. This is why benefits and tolerability have to be managed together.
Why some patients respond to lower doses while others need titration
People vary in medication sensitivity, appetite biology, baseline weight, glucose metabolism, and side effect risk. A lower dose may feel noticeable for one person and too mild for another.
Clinical guidelines for obesity care stress long-term follow-up, treatment response, side effects, and cardiometabolic risk, not dose alone 9. For diabetes, clinicians also consider A1C, glucose patterns, and hypoglycemia risk when tirzepatide is used with other glucose-lowering drugs 2, 10.
Why appetite response, side effects, labs, and goals should be clinician-guided
Tirzepatide can affect appetite, digestion, blood sugar, and hydration. A clinician can help decide whether a dose is too low to meet goals, too high for tolerability, or unsafe because of a medical history or medication interaction 1, 2.
How much does tirzepatide microdosing cost?
Tirzepatide microdosing cost depends on whether the medication is brand-name or compounded, the form, the pharmacy, and what is included in follow-up. At Chia, tirzepatide plans currently start at $249/month for tablets and $299/month for injections.
Why price varies by brand-name, compounded, oral, and injectable options
Brand-name Zepbound and Mounjaro pricing may depend on insurance, savings programs, dose, and pharmacy. Compounded tirzepatide pricing depends on the clinical program, pharmacy, formulation, dose plan, and follow-up model.
Compounded tirzepatide via a 503A pharmacy is different from a brand-name FDA-approved product. It is prescribed for an individual patient by a licensed clinician and compounded by a state-licensed pharmacy, but it is not FDA-approved 8.
What to look for in a transparent monthly price
- Whether the price includes the medication, provider review, follow-up, supplies, and shipping.
- Whether dose changes affect the monthly cost.
- Whether the pharmacy is a state-licensed 503A compounding pharmacy.
- Whether a prescription is required and reviewed by a licensed US clinician.
- Whether the program explains side effects, contraindications, and follow-up clearly.
Comparison table: brand-name Zepbound, compounded tirzepatide, and Chia tirzepatide pricing
| Option | Form | Price information | Clinical review | Important limit |
|---|---|---|---|---|
| Brand-name Zepbound | Injection | Varies by insurance, savings programs, and pharmacy | Prescription required | FDA-approved product, but cost and access vary |
| Compounded tirzepatide | Forms vary by prescriber and pharmacy | Varies by clinic, pharmacy, dose plan, and follow-up | Prescription required | Compounded medications are not FDA-approved |
| Chia tirzepatide | Tablets or injection | Plans currently start at $249/month for tablets and $299/month for injections | Licensed US provider review; prescription not guaranteed | Microdosing plans are available only when clinically appropriate |
3-min quiz
Considering a lower-dose tirzepatide plan?
Chia offers tirzepatide tablets and injections after a licensed US provider reviews your health questionnaire. Plans currently start at $249/month for tablets and $299/month for injections. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
Microdosing tirzepatide at Chia: tablets or injections
At Chia, tirzepatide is available as compounded tablets or injections, and microdosing plans are available when a licensed provider decides they are clinically appropriate. We use an online visit, licensed-provider review, US 503A pharmacy compounding, and home delivery.
Chia tirzepatide options: tablets from $249/month and injections from $299/month
| Chia option | Current starting price | How it may fit a patient’s life | Clinical note |
|---|---|---|---|
| Compounded tirzepatide tablets | From $249/month | May appeal to patients who prefer not to inject | Provider-guided dosing; eligibility required |
| Compounded tirzepatide injection | From $299/month | May appeal to patients who prefer injectable routines | Provider-guided dosing; eligibility required |
Microdosing plans are available when a licensed provider decides they are clinically appropriate
Our providers do not use a one-size-fits-all dose plan. They review your health history, goals, medications, side effect risk, and follow-up needs before deciding whether tirzepatide is appropriate and whether a low-dose approach makes sense.
How Chia works: online questionnaire, licensed US provider review, 503A pharmacy, home delivery
- 1Start with a short online health questionnaire through Chia’s eligibility quiz.
- 2A licensed US provider reviews your information and prescribes only when clinically appropriate.
- 3If prescribed, medication is compounded by a US state-licensed 503A pharmacy.
- 4Medication ships to your door, and you can message your care team through the patient portal between visits.
Some patients also pair GLP-1 care with related Chia protocols, such as Weight + Energy, which includes NAD+ injection with a choice of GLP-1, or Weight + Muscle, which includes sermorelin injection with a choice of GLP-1. These protocols still require provider review and are prescribed only when appropriate.
When to use the eligibility quiz or DoctorMCP at mcp.chia.health
Most patients start through the eligibility quiz. If you use an AI assistant or agent that can connect with medical access tools, DoctorMCP at mcp.chia.health can help request a Chia clinical evaluation pathway; a licensed provider still reviews your health information, and a prescription is never guaranteed.
Is tirzepatide microdosing FDA-approved?
No. Tirzepatide microdosing is not an FDA-approved dosing category, and doses below 2.5 mg once weekly are not part of the approved Zepbound or Mounjaro dose labels 1, 2.
Approved tirzepatide products vs compounded tirzepatide
Zepbound and Mounjaro are FDA-approved brand-name tirzepatide products for their labeled uses. Compounded tirzepatide is prepared for an individual patient under a prescription, but compounded drugs are not FDA-approved and do not go through FDA premarket review for safety, effectiveness, or quality 8.
What “off-label” and “not FDA-approved” mean for patients
Off-label use means a licensed clinician is using a medication in a way that is not described in the FDA-approved label. “Not FDA-approved” means the compounded formulation itself has not been reviewed by FDA as a finished drug product 8.
Why compounded medications are different from FDA-approved brand-name drugs
The key safety line is licensed versus unlicensed care. A licensed provider and state-licensed 503A pharmacy offer medical review, prescription oversight, and pharmacy standards. No-prescription “research chemical” sources do not provide the same clinical or pharmacy safeguards 8.
What are the possible risks of taking too little tirzepatide?
The main concern with very low-dose tirzepatide is not only side effects. It is also limited evidence: doses below approved ranges may lead to weak or inconsistent appetite effects, unclear metabolic benefit, and delayed treatment adjustment.
Limited evidence for doses below approved ranges
Large tirzepatide obesity trials studied 5 mg, 10 mg, and 15 mg maintenance doses, not long-term microdoses below 2.5 mg 3. SURMOUNT-3 and SURMOUNT-4 also evaluated tirzepatide using structured trial dosing and follow-up, not patient-directed microdosing 4, 5.
Possible under-treatment or inconsistent appetite effects
If a dose is too low for a person’s biology, appetite, satiety, and weight-related markers may not change enough to meet the care goal. On the other hand, even low doses can still cause nausea, constipation, diarrhea, reflux, or reduced intake, so “lower” does not mean “risk-free” 1.
Why changing dose or spacing injections without a clinician can be risky
Tirzepatide has a long half-life of about 5 days, and the FDA labels are built around once-weekly dosing 1, 2. Stretching doses, splitting doses, or changing timing can make side effects and appetite response harder to track.
What should you ask a clinician before trying a low dose?
Before trying a low-dose tirzepatide plan, ask about eligibility, contraindications, side effects, follow-up, and how success will be measured over the first few months. A safe plan should include more than a number.
Eligibility, BMI, metabolic health, medications, and contraindications
- Do my BMI, weight-related comorbidities, or metabolic labs support medication treatment?
- Do I have a history that raises concern, such as pancreatitis, gallbladder disease, severe gastrointestinal disease, medullary thyroid carcinoma, MEN2, kidney injury, or pregnancy plans?
- Am I taking insulin, sulfonylureas, or other medications that could increase hypoglycemia risk?
- Would tirzepatide, semaglutide injection, or another plan better fit my goals and risk profile?
Side effects to discuss before starting
Ask what to do if you develop nausea, vomiting, diarrhea, constipation, dehydration, abdominal pain, reflux, low blood sugar symptoms, or signs of gallbladder disease. The FDA labels include warnings for pancreatitis, gallbladder disease, kidney injury, and hypoglycemia risk with insulin or sulfonylureas 1, 2.
How follow-up and dose adjustment should work
A good follow-up plan tracks appetite, weight trend, side effects, nutrition, strength, labs when appropriate, and medication access. Dose titration should be a shared clinical decision, not a reaction to a social media chart 9.
Usually, no. 2.5 mg once weekly is the FDA-approved starting dose for Zepbound and Mounjaro. The Zepbound label describes it as a starting dose, not a maintenance dose. Doses below 2.5 mg are more often what people mean by “microdose.”
For FDA-approved Zepbound and Mounjaro labeling, the smallest listed starting dose is 2.5 mg once weekly. Doses below that are not an FDA-approved dose category and should not be copied from online examples.
Cost varies by clinic, pharmacy, form, follow-up, and dose plan. At Chia, tirzepatide plans currently start at $249/month for tablets and $299/month for injections. A licensed provider must review your health information, and a prescription is not guaranteed.
Do not split, stretch, or change any tirzepatide dose without clinician guidance. Dose splitting can create safety, sterility, and accuracy problems, and it may make side effects or appetite response harder to manage.
No. Tablets and injections are different forms and may be prescribed differently. Chia offers compounded tirzepatide tablets and injections, but the right form depends on a licensed provider’s review of your goals, history, and safety factors. Compounded medications are not FDA-approved.
No. Compounded medications are not FDA-approved. They are prepared by a compounding pharmacy for an individual patient when prescribed by a licensed clinician, but they do not have FDA-evaluated outcomes data like an approved brand-name product.
A lower starting approach may be considered by some clinicians for tolerability, but it is not risk-free and has limited evidence. Nausea, vomiting, diarrhea, constipation, reflux, dehydration, and other side effects can still occur.
Yes. Tirzepatide requires a prescription. You can start through Chia’s online eligibility quiz, and AI assistants and agents can request a clinical evaluation pathway via mcp.chia.health. A prescription is never guaranteed.
3-min quiz
Start with a clinician-reviewed plan
If you are considering tirzepatide, Chia can help you start with an online health questionnaire and licensed US provider review. Tirzepatide tablets currently start at $249/month and injections at $299/month through Chia tirzepatide. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
References
- 1.US Food and Drug Administration. Zepbound (tirzepatide) injection, prescribing information. 2025.
- 2.US Food and Drug Administration. Mounjaro (tirzepatide) injection, prescribing information. 2025.
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- 4.Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023.
- 5.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- 6.Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- 7.US Food and Drug Administration. Ozempic (semaglutide) injection, prescribing information. 2025.
- 8.US Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
- 9.Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
- 10.American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
